Treatment of Immune Thrombocytopenic Purpura in Adults

Seminars in Hematology

Volumn 43, Issue SUPPL. 5, 2006, Pages S3-

  Bussel, James ^a  

^a Division of Hematology and Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMG 531; ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DEXAMETHASONE; ELTROMBOPAG; ETOPOSIDE; HEMATOLOGIC AGENT; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PNEUMOCOCCUS VACCINE; PREDNISONE; PROCARBAZINE; RHESUS D ANTIBODY; RITUXIMAB; THROMBOPOIETIN; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ARTICLE; AUTOIMMUNITY; B CELL LYMPHOMA; BACTERIAL INFECTION; BLOOD DISEASE; BRAIN HEMORRHAGE; CHILL; CLINICAL TRIAL; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; HEMATOLOGIC DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NEPHROTOXICITY; PRIORITY JOURNAL; SEPSIS; SPLENECTOMY; SURGICAL TECHNIQUE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VACCINATION;

EID: 33745669328     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.04.009     Document Type: Article

References (56)

1. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 126 (1997) 307-314
2. Frederiksen H., and Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 94 (1999) 909-913
3. Neylon A.J., Saunders P.W.G., Howard M.R., Proctor S.J., Taylor P.R.A., and Northern Regional Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults. A prospective study of a population-based cohort of 245 patients. Br J Haematol 122 (2003) 966-974
4. British Committee for Standards in Haematology and General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 120 (2003) 574-596
5. Cines D.B., and Bussel J.B. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 106 (2005) 2244-2251
6. Cines D.B., and McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 56 (2005) 425-442
7. Cohen Y.C., Djulbegovic B., Shamai-Lubovitz O., and Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 160 (2001) 1630-1638
8. Cortelazzo S., Finazzi G., Buelli M., Molteni A., Viero P., and Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 77 (1991) 31-33
9. Butros L.J., and Bussel J.B. Intracranial hemorrhage in immune thrombocytopenic purpura. A retrospective analysis. J Pediatr Hematol Oncol 25 (2003) 660-664
10. Cines D.B., Bussel J.B., McMillan R.B., and Zehnder J.L. Congenital and acquired thrombocytopenia. Hematology (Am Soc Hematol Educ Program) (2004) 390-406
11. George J.N., Woolf S.H., Raskob G.E., Wasser J.S., Aledort L.M., Ballem P.J., et al. Idiopathic thrombocytopenic purpura. A practice guideline developed by explicit methods for the American Society of Hematology. Blood 88 (1996) 3-40
12. Newman G.C., Novoa M.V., Fodero E.M., Lesser M.L., Woloski B.M.R., and Bussel J.B. A dose of 75 μg/kg/d of IV anti-D increases the platelet count more rapidly and for a longer period of time than does 50 g/kg/d in adults with immune thrombocytopenic purpura (ITP). Br J Haematol 112 (2001) 1076-1078
13. George J.N., Raskob G.E., Vesely S.K., Moore Jr. D., Lyons R.M., Cobos E., et al. Initial management of immune thrombocytopenic purpura in adults. A randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol 74 (2003) 161-169
14. Bussel J.B., Graziano J.N., Kimberly R.P., Pahwa S., and Aledort L.M. Intravenous anti-D treatment of immune thrombocytopenic purpura. Analysis of efficacy, toxicity, and mechanism of effect. Blood 77 (1991) 1884-1893
15. Cooper N., Heddle N.M., Haas M., Reid M.E., Lesser M.L., Fleit H.B., et al. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms. Modulation of cytokine and platelet responses to IV anti-D by FcγRIIa and FcγRIIIa polymorphisms. Br J Haematol 124 (2004) 511-518
16. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIg mediated through the inhibitory Fc receptor. Science 291 (2001) 484-486
17. Andersen J.C. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 330 (1994) 1560-1564
18. Cheng Y., Wong R.S.M., Soo Y.O.Y., Chui C.H., Lau F.Y., Chan N.P., et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 349 (2003) 831-836
19. Cooper N., Woloski B.M., Fodero E.M., Novoa M., Leber M., Beer J.H., and Bussel J.B. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?. Blood 99 (2002) 1922-1927
20. Grillo-López A.J., Hedrick C., Rashford M., and Benyunes M. Rituximab. Ongoing and future clinical development. Semin Oncol 29 (2002) 105-112
21. Cooper N., Stasi R., Cunningham-Rundles S., Feuerstein M.A., Leonard J.P., Amadori S., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenia purpura. Br J Haematol 125 (2004) 232-239
22. Bennett C.M., Rogers Z.R., Kinnamon D.D., Bussel J.B., Mahoney D.H., Abshire T.C., et al. Prospective phase I/II study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107 (2005) 2639-2642
23. Wang J., Wiley J.M., Luddy R., Greenberg J., Feuerstein M.A., and Bussel J.B. Chronic immune thrombocytopenic purpura in children. assessment of rituximab treatment. J Pediatr 146 (2005) 217-221
24. Hasan A.N., and Bussel J.B. Re-treatment with rituximab in ITP. comparison of standard dose with 2 forms of augmented rituximab. Blood 106 (2005) 1237 (abstr)
25. Stasi R., Stipa E., Masi M., Cecconi M., Scimo M.T., Oliva F., et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 98 (1995) 436-442
26. Kojouri K., Vesely S.K., Terrell D.R., and George J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura. A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104 (2004) 2623-2634
27. Schwartz J., Eldor A., Gillis S., Guinta A., Leber M., and Bussel J.B. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 72 (2003) 94-98
28. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Morb Mortal Wkly Rep 42 (1993) 1-11
29. + memory B cells but protective antibody responses to pneumococcal vaccination. Blood 104 (2004) 3025 (abstr)
30. Fabris F., Tassan T., Ramon R., Carraro G., Randi M.L., Luzzatto G., et al. Age as the major predictor of long-term response to splenectomy in immune thrombocytopenic purpura. Br J Haematol 112 (2001) 637-640
31. Marcaccio M.J. Laparoscopic splenectomy in chronic idiopathic thrombocytopenic purpura. Semin Hematol 37 (2000) 267-274
32. Cines D.B., and Blanchette V. Idiopathic thrombocytopenic purpura. N Engl J Med 364 (2002) 995-1008
33. Vesely S.K., Perdue J.J., Rizvi M.A., Terrell D.R., and George J.N. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy. Ann Intern Med 140 (2004) 112-120
34. Levy A.S., Cunningham-Rundles S., Mazza B., Simm M., Gorlick R., and Bussel J. High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. Br J Haematol 118 (2002) 836-838
35. Kappers-Klunne M.C., and van't Veer M.B. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenia purpura refractory to corticosteroids or splenectomy. Br J Haematol 114 (2001) 121-125
36. Godeau B., Durand J.-M., Roudot-Thoraval F., Tenneze A., Oksenhendler E., Kaplanski G., et al. Dapsone for chronic autoimmune thrombocytopenic purpura. A report of 66 cases. Br J Haematol 97 (1997) 336-339
37. Scaradavou A., Woo B., Woloski B.M.R., Cunningham-Rundles S., Ettinger L.J., Aledort L.M., et al. Intravenous anti-D treatment of immune thrombocytopenic purpura. Experience in 272 patients. Blood 89 (1997) 2689-2700
38. Hou P., Pang J., Shi Y., Zhang C., Qin P., Zhao C., et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 70 (2003) 353-357
39. Figueroa M., Gehlsen J., Hammond D., Ondreyco S., Piro L., Pomeroy T., et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 328 (1993) 1226-1229
40. Huhn R.D., Fogarty P.F., Nakamura R., Read E.J., Leitman S.F., Rick M.E., et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 101 (2003) 71-77
41. Kuter D., Bussel J.B., Aledort L.M., et al. A phase 2 placebo controlled study evaluating the platelet response and safety of weekly dosing with a novel thrombopoietic protein (AMG531) in thrombocytopenic adult patients (pts) with immune thrombocytopenic purpura (ITP). Blood 114 suppl 1 (2004) 148a (abstr)
42. Newland A., Caulier M.T., Schipperus M.R., et al. An open-label, unit dose-finding study evaluating the safety and platelet response of a novel thrombopoietic protein (AMG531) in thrombocytopenic adult patients (pts) with immune thrombocytopenic purpura (ITP). Blood 104 suppl 1 (2004) 567a (abstr)
43. Bussel J.B., George J.N., Kuter D.J., Wasser J.S., Aledort L.M., Chen M.-G., and Nichol J.L. An open-label, dose-finding cohort study evaluating the safety of and platelet response to a novel thrombopoietic protein (AMG531) in thrombocytopenic patients with immune thrombocytopenic purpura (ITP). Blood 102 (2003) 86a (abstr)
44. Bussel J.B., Mukherjee R., and Stone A.J. A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol 66 (2001) 172-177
45. Snyder Jr. H.W., Cochran S.K., Balint Jr. J.P., Bertram J.H., Mittelman A., Guthrie Jr. T.H., et al. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood 79 (1992) 2237-2245
46. Blanchette V.S., and Price V. Childhood chronic immune thrombocytopenic purpura. Unresolved issues. J Pediatr Hematol Oncol 25 suppl 1 (2003) S28-S33
47. Caulier M.T., Rose C., Roussel M.T., Huart C., Bauters F., and Fenaux P. Pulsed high-dose dexamethasone in refractory chronic idiopathic thrombocytopenic purpura. A report on 10 cases. Br J Haematol 91 (1995) 477-479
48. Kuwana M., Kawakami Y., and Ikeda Y. Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction. Implications for treatment of immune thrombocytopenic purpura. Blood 101 (2003) 621-623
49. Lim S.H., Hale G., Marcus R.E., Waldmann H., and Baglin T.P. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol 84 (1993) 542-544
50. Emilia G., Longo G., Luppi M., Gandini G., Morselli M., Ferrara L., et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood 97 (2001) 812-814
51. Kohda K., Kuga T., Kogawa K., Kanisawa Y., Koike K., Kuroiwa G., et al. Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol 118 (2002) 584-588
52. Michel M., Cooper N., Jean C., Frissora C., and Bussel J.B. Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura?. Blood 103 (2003) 890-896
53. Gill K.K., and Kelton J.G. Management of idiopathic thrombocytopenic purpura in pregnancy. Semin Hematol 37 (2000) 275-289
54. Fujimura K., Harada Y., Fujimoto T., Kuramoto A., Ikeda Y., Akatsuka J., et al. Nationwide study of idiopathic thrombocytopenic purpura in pregnant women and the clinical influence on neonates. Int J Hematol 75 (2002) 426-433
55. Samuels P., Bussel J.B., Braitman L.E., Tomaski A., Druzin M.L., Mennuti M.T., et al. Estimation of the risk of thrombocytopenia in the offspring of pregnant women with presumed immune thrombocytopenic purpura. N Engl J Med 323 (1990) 229-235
56. Michel M., Novoa M.V., and Bussel J.B. Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. Br J Haematol 123 (2003) 142-146